Eli Lilly (LLY) EVP Skovronsky receives 15,548-share stock grant in Form 4

Rhea-AI Filing Summary

Eli Lilly & Co. executive Daniel Skovronsky reported an acquisition of company common stock through a grant or award. On 02/09/2026, he received 15,547.862 shares at a price of $1,044.67 per share, bringing his directly held stake to 160,071.725 shares, with additional indirect holdings through a trust and spouse-related entities.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Skovronsky Daniel

(Last) (First) (Middle)

LILLY CORPORATE CENTER

(Street)

INDIANAPOLIS IN 46285

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ELI LILLY & Co [ LLY ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, CS&PO & Pres. LRL

3. Date of Earliest Transaction (Month/Day/Year)
02/09/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/09/2026		A		15,547.862	A	$1,044.67	160,071.725	D
Common Stock								72,359	I	By Trust(1)
Common Stock								547	I	By spouse(1)
Common Stock								2,710	I	By spouse's SLAT(1)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.

Remarks:

	/s/ Jonathan Groff for Daniel Skovronsky, pursuant to authorization on file	02/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Eli Lilly (LLY) report for Daniel Skovronsky?

Eli Lilly EVP Daniel Skovronsky reported receiving a grant or award of 15,547.862 shares of common stock on 02/09/2026 at $1,044.67 per share. This transaction increased his directly held position to 160,071.725 shares, as disclosed in the Form 4 filing.

Was the Eli Lilly (LLY) Form 4 transaction a stock grant or an open-market purchase?

The Form 4 shows a stock grant or award acquisition, not an open-market purchase. Transaction code A indicates a grant, award, or other acquisition, with 15,547.862 Eli Lilly common shares credited at a reference price of $1,044.67 per share on 02/09/2026.

How many Eli Lilly (LLY) shares does Daniel Skovronsky hold directly after the transaction?

After the reported grant, Daniel Skovronsky directly holds 160,071.725 shares of Eli Lilly common stock. This figure reflects his direct ownership only and excludes additional indirect positions reported through a trust and spouse-related entities in the same Form 4.

What indirect Eli Lilly (LLY) holdings related to Daniel Skovronsky are disclosed?

The filing lists indirect holdings of 72,359 Eli Lilly shares by a trust, 547 shares by his spouse, and 2,710 shares by his spouse’s SLAT. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest in them.

What does the beneficial ownership disclaimer mean in the Eli Lilly (LLY) Form 4?

The Form 4 states that the reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest. This means he does not claim full beneficial ownership beyond any direct economic interest he may have in those indirect holdings.

What is Daniel Skovronsky’s role at Eli Lilly (LLY) mentioned in the Form 4?

The Form 4 identifies Daniel Skovronsky as an officer of Eli Lilly with the title EVP, CS&PO & President, LRL. This clarifies he is a senior executive of the company, which triggers ongoing insider reporting obligations for his transactions in Eli Lilly stock.